In building our portfolio, we continually evaluate the rare disease landscape and unmet needs. Each of our portfolio companies has a unique pipeline focusing on a distinct area of biology to address the great unmet need associated with “the long tail of disease.” Our programs are first-in-class and internally generated, each representing a pipeline-in-a-product opportunity that can treat numerous rare diseases.
Electra Therapeutics is expanding the possibilities of targeting signal-regulatory protein (SIRP) to develop breakthrough therapies for immunological diseases and cancer.
Vega Therapeutics is focused on developing novel therapies to address overlooked needs in rare blood disorders, starting with von Willebrand disease (VWD).
We are currently interrogating numerous other areas of biology and continually building our portfolio. Details on additional portfolio companies will be coming soon.
Expanded Access to Investigational Medicines Prior to Regulatory Approval
At Star Therapeutics, we aim to provide patients access to our investigational therapies in the most clinically appropriate manner. Star Therapeutics does not currently accept or grant requests for expanded access to any of our investigational therapies outside of clinical trials.
We look forward to connecting with you